Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

intervet international b.v. - porcin parvovirus, stamme 014 (inaktiveret) - injektionsvæske, suspension - svin

Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

zoetis finland oy - porcint parvovirus, stamme nadl-2 (inaktiveret) - injektionsvæske, suspension - svin

Unia Europejska - duński - EMA (European Medicines Agency)

ceva santé animale - inaktiveret coxiella burnetii vaccine, stamme nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Unia Europejska - duński - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinant verotoksin 2e af e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svin - aktiv immunisering af smågrise fra 2 dage gammel for at forhindre, at reducere dødelighed og kliniske tegn på ødem sygdomme (forårsaget af verotoksin 2e produceret af e. coli) og for at reducere tabet af daglig vægtforøgelse i efterbehandlingstiden i lyset af infektioner med verotoxin 2e-producerende e. coli indtil slagtning fra 164 dage.

Unia Europejska - duński - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - reduktion af neonatal enterotoxicosis af smågrise, der er forårsaget af e. coli-stammer, der udtrykker adhesinerne f4ab, f4ac, f4ad, f5, f6 og f41, i de første dage af livet.

Unia Europejska - duński - EMA (European Medicines Agency)

intervet international bv - babesia canis, inactivated, babesia rossi, inactivated - immunologier til canidae - hunde - til aktiv immunisering af hunde på seks måneder eller ældre mod babesia canis for at reducere sværhedsgraden af ​​kliniske tegn forbundet med akut babesiose (b. canis) og anæmi som målt ved pakket cellevolumen. immunitetens begyndelse: tre uger efter grundvaccinationen. immunitetens varighed: seks måneder efter den sidste (re) vaccination.

Unia Europejska - duński - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Unia Europejska - duński - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immunitetsbegyndelser er blevet påvist 1 uge efter primærvaccinationskursus for rhinotracheitis, calicivirus og chlamydophila felis komponenter. varigheden af ​​immunitet er 1 år efter den sidste (re) vaccination.

Unia Europejska - duński - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Unia Europejska - duński - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrin har vist sig en uge efter primærvaccinationskursus for rhinotracheitis, calicivirus, chlamydophila felis og panleucopenia komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.